• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion.

作者信息

Swami Umang, Ma Deqin, Zhang Jun

机构信息

Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, Iowa.

Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa.

出版信息

J Thorac Oncol. 2018 Jul;13(7):e129-e130. doi: 10.1016/j.jtho.2018.03.034.

DOI:10.1016/j.jtho.2018.03.034
PMID:29935854
Abstract
摘要

相似文献

1
Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion.一名患有EGFR L747S复合突变和19外显子缺失患者对厄洛替尼的反应
J Thorac Oncol. 2018 Jul;13(7):e129-e130. doi: 10.1016/j.jtho.2018.03.034.
2
De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.在未经TKI治疗的EGFR-L858R突变肺腺癌中，新发ERBB2扩增导致对厄洛替尼产生内在抗性。
Lung Cancer. 2017 Dec;114:108-110. doi: 10.1016/j.lungcan.2017.08.018. Epub 2017 Aug 24.
3
Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma.在厄洛替尼耐药的肺腺癌中，MET基因拷贝数的异质性和表皮生长因子受体（EGFR）突变导致原发灶和转移灶对克唑替尼产生不一致的反应。
Lung Cancer. 2018 Oct;124:317-319. doi: 10.1016/j.lungcan.2018.03.016. Epub 2018 Mar 17.
4
Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.一名未经治疗的肺腺癌患者中酪氨酸激酶抑制剂敏感和耐药的EGFR突变共存及对厄洛替尼的反应
J Thorac Oncol. 2014 Jul;9(7):e55-e57. doi: 10.1097/JTO.0000000000000197.
5
Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.肝转移与厄洛替尼作为肺腺癌患者二线/三线治疗的疗效不佳相关。
Med Sci Monit. 2016 Jan 26;22:276-83. doi: 10.12659/msm.896607.
6
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.曾接受治疗的晚期肺腺癌患者中吉非替尼对比厄洛替尼的随机 III 期研究：WJOG5108L
J Clin Oncol. 2016 Sep 20;34(27):3248-57. doi: 10.1200/JCO.2015.63.4154. Epub 2016 Mar 28.
7
Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?厄洛替尼用于并存典型支气管类癌和晚期肺腺癌：表皮生长因子受体突变状态重要吗？
Anticancer Drugs. 2018 Mar;29(3):281-285. doi: 10.1097/CAD.0000000000000587.
8
Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).西班牙裔人群中表皮生长因子受体突变阳性肺腺癌患者对厄洛替尼获得性耐药（CLICaP）
Target Oncol. 2017 Aug;12(4):513-523. doi: 10.1007/s11523-017-0497-2.
9
Genome-wide DNA Methylation Analysis Reveals as a Novel Epigenetic Target for 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment.全基因组 DNA 甲基化分析显示 是 19 号缺失肺腺癌诱导厄洛替尼治疗的新型表观遗传靶标。
Clin Cancer Res. 2017 Sep 1;23(17):5003-5014. doi: 10.1158/1078-0432.CCR-16-2688. Epub 2017 May 10.
10
Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.厄洛替尼全程治疗非小细胞肺癌合并妊娠成功案例
JAMA Oncol. 2015 Sep;1(6):838-40. doi: 10.1001/jamaoncol.2015.1300.

引用本文的文献

1
Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.表皮生长因子受体的核输出信号突变增强癌细胞的恶性表型。
Am J Cancer Res. 2023 Apr 15;13(4):1209-1239. eCollection 2023.